SCHEMBL6035210

SCHEMBL6035210

CCCc1nn(-c2ccc(C(F)(F)F)cn2)cc1CCCOc1c(CC)cccc1CC(=O)O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GCGR P47871 2/20 0.36
SMN1; SMN2 Q16637 5/20 0.36
HPGD P15428 1/20 0.36
HCRTR1 O43613 2/20 0.34
HCRTR2 O43614 2/20 0.34
KDM4E B2RXH2 2/20 0.34
NPC1 O15118 1/20 0.34
MAPT P10636 1/20 0.34
RAB9A P51151 1/20 0.34
HDAC4 P56524 1/20 0.34
LMNA P02545 1/20 0.34
LIPE Q05469 3/20 0.34
GCG P01275 1/20 0.33
EGLN1 Q9GZT9 1/20 0.33
AGBL2 Q5U5Z8 1/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.32
IDE P14735 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6035945 0.93 GCGR (0.35) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6035417 0.93 SMN1; SMN2 (0.36) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6034571 0.93 GCGR (0.35) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6035540 0.92 PPARG (0.40) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6035752 0.92 SMN1; SMN2 (0.41) SMN1; SMN2HPGDKDM4ELMNA
SCHEMBL6035477 0.91 GCGR (0.35) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6034630 0.90 GCGR (0.34) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2
SCHEMBL6035208 0.90 HCRTR1 (0.38) GCGRSMN1; SMN2HCRTR1HCRTR2KDM4E
SCHEMBL6035863 0.89 PPARD (0.41) SMN1; SMN2KDM4ELMNALIPEPTGDR2
SCHEMBL6035821 0.89 SMN1; SMN2 (0.36) GCGRSMN1; SMN2HPGDHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148858-A1 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity GPR119, SLC5A1, CYP4B1 GCGR 93/4885SMN1; SMN2 4408/4885HPGD 3297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.